ESC Professional Premium Access

SGLT2 inhibitors: pearls from recent trials and surveys

Event: ESC Congress 2022
Topic: Chronic Heart Failure
Session type: Abstract Sessions
Date: 28 August 2022
Time: 09:00 - 09:50

Congress Session

4 presentations in this session

The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

Speaker: Assistant Professor E. Maor (Tel Aviv, IL)
Thumbnail

Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

Speaker: Doctor C. Adamson (Glasgow, GB)
Thumbnail

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Speaker: Doctor A. Pandey (Dallas, US)
Thumbnail

Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)
Thumbnail

4 speakers from this session

Assistant Professor Elad Maor

Sheba Medical Center, Tel Aviv (Israel)
0 follower

Doctor Carly Adamson

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Ambarish Pandey

University of Texas Southwestern Medical Center, Dallas (United States of America)
0 follower

Doctor Kieran Docherty

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
2 presentations
0 follower

This platform is supported by

logo Novo Nordisk